My watch list  


Systematic (IUPAC) name
CAS number 107233-08-9
ATC code  ?
PubChem 83898
DrugBank APRD00224
Chemical data
Formula C10H17NOS 
Mol. mass 489.565 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding < 20%
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping. [1]

See also

  • Sjögren's syndrome
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cevimeline". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE